Hypergammaglobulinemia Before Starting DAA Therapy Is A Strong Predictor of Disease Progression in Cirrhotic Patients Even After HCV Clearance

Overview

Journal J Pers Med

Date 2022 Dec 29

PMID 36579534

Authors

Maria Stella Franze

Roberto Filomia

Gaia Caccamo

Concetta Pitrone

Angela Alibrandi

Carlo Saitta

Amalia Rita Caspanello

Clelia Asero

Vittoria Arcadi

Giovanni Raimondo

Irene Cacciola

Affiliations

Soon will be listed here.

Abstract

The predictive factors of long-term clinical benefits in patients with hepatitis C virus (HCV)—related liver cirrhosis after Direct Antiviral Agents (DAA) treatment are still undefined. The aim of this study was to identify any predictors of liver failure, hepatocellular carcinoma (HCC) and/or death in patients with compensated liver cirrhosis who achieved the sustained virological response (SVR). To this purpose, 324 consecutive cirrhotic patients who started DAA treatment from 1 April 2015 to 31 December 2016 were retrospectively analyzed. All patients were followed up for a median time of 63 months (range 19−77) through clinical/biochemical/instrumental examinations performed at baseline and after stopping the DAA treatment. At the end of the evaluation, 230 (71%) individuals showed stable clinical liver disease over time, 43 (13.3%) developed HCC, and 24 (7.4%) developed hepatic decompensation without HCC. Overall, 49 (15,1%) patients died. Multivariate regression analysis showed that hepatic decompensation was significantly associated with at baseline older age, higher liver stiffness, higher spleen longitudinal size values and hypergammaglobulinemia (p = 0.003, p = 0.005, p = 0.001, p = 0.029, respectively). HCC development was significantly associated with hypergammaglobulinemia (p < 0.001). Death was associated with older age and hypergammaglobulinemia (p < 0.001 and p = 0.007, respectively). Finally, survival analysis confirmed that patients with gamma globulin levels ≥ 1.8 gr/dl had a significantly higher risk of death compared to those with gamma globulin levels < 1.8 gr/dl (p < 0.001). In conclusion, hypergammaglobulinemia before starting DAA therapy represents a strong predictor of hepatic decompensation, HCC and death in cirrhotic patients even after HCV clearance.

References

Lens S, Alvarado-Tapias E, Marino Z, Londono M, Llop E, Martinez J . Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. Gastroenterology. 2017; 153(5):1273-1283.e1. DOI: 10.1053/j.gastro.2017.07.016. View

Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D . Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. Gastroenterology. 2018; 155(5):1436-1450.e6. DOI: 10.1053/j.gastro.2018.07.015. View

Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A . Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2018; 155(2):411-421.e4. DOI: 10.1053/j.gastro.2018.04.008. View

Cacciola I, Russo G, Filomia R, Pitrone C, Caccamo G, Giandalia A . Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis. Liver Int. 2021; 41(9):2059-2067. PMC: 8506140. DOI: 10.1111/liv.14905. View

Ioannou G, Green P, Berry K . HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2017; . PMC: 5837901. DOI: 10.1016/j.jhep.2017.08.030. View

Krassenburg L, Maan R, Ramji A, Manns M, Cornberg M, Wedemeyer H . Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. J Hepatol. 2020; 74(5):1053-1063. DOI: 10.1016/j.jhep.2020.11.021. View

Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, Chemello L . Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study. J Hepatol. 2018; 69(2):345-352. DOI: 10.1016/j.jhep.2018.03.009. View

Butt A, Yan P, Shaikh O, Lo Re 3rd V, Abou-Samra A, Sherman K . Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study. J Hepatol. 2020; 73(2):277-284. DOI: 10.1016/j.jhep.2020.02.022. View

. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69(1):182-236. DOI: 10.1016/j.jhep.2018.03.019. View

10.

. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology. 1994; 20(1):15-20. View

11.

Duan Z, Li L, Li J, Zhou S . Validation of the Combined Model Based on Platelet Count and Albumin to Rule out High-Risk Varices in Liver Cirrhosis. Biomed Res Int. 2020; 2020:5783748. PMC: 7374218. DOI: 10.1155/2020/5783748. View

12.

Verna E, Morelli G, Terrault N, Lok A, Lim J, Di Bisceglie A . DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. J Hepatol. 2020; 73(3):540-548. DOI: 10.1016/j.jhep.2020.03.031. View

13.

DAmbrosio R, Degasperi E, Anolli M, Fanetti I, Borghi M, Soffredini R . Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. J Hepatol. 2021; 76(2):302-310. DOI: 10.1016/j.jhep.2021.09.013. View

14.

Kondili L, Gaeta G, Brunetto M, Di Leo A, Iannone A, Santantonio T . Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. PLoS One. 2017; 12(10):e0185728. PMC: 5627924. DOI: 10.1371/journal.pone.0185728. View

15.

De Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C . Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022; 76(4):959-974. PMC: 11090185. DOI: 10.1016/j.jhep.2021.12.022. View

16.

Calvaruso V, Celsa C, DAmbrosio R, Simone F, Petta S, Cacciola I . RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices. Am J Gastroenterol. 2022; 117(11):1816-1824. DOI: 10.14309/ajg.0000000000001878. View

17.

Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato M, Ronchi G . Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut. 2007; 56(7):968-73. PMC: 1994385. DOI: 10.1136/gut.2006.111302. View

18.

Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C . Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019; 393(10179):1453-1464. DOI: 10.1016/S0140-6736(18)32111-1. View

19.

. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018; 69(2):461-511. DOI: 10.1016/j.jhep.2018.03.026. View

20.

Calvaruso V, Craxi A . Hepatic benefits of HCV cure. J Hepatol. 2020; 73(6):1548-1556. DOI: 10.1016/j.jhep.2020.08.006. View